Hispanic Broadcasting

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 277 in Hispanic Broadcasting

  1. No Hiding From Respirageddon For BoehringerRead the original story w/Photo

    18 hrs ago | Seeking Alpha

    The decline was due to discounts and rebates implemented to keep the COPD drug on US formularies, volume having remained pretty constant, Boehringer's chairman, Andreas Barner, told yesterday's annual press conference. The fact that the group expects the business overall to return to moderate growth in 2015 could seem surprising, as might its lifecycle management strategy.

    Comment?

  2. DaVita HealthCare (DVA), Hospira (HSP), Berkshire Hathaway (BRK.A)...Read the original story w/Photo

    19 hrs ago | Insider Monkey

    Ben Levine, Andrew Manuel and Stefan Renold's LMR Partners has filed its latest 13F, and there has been a good deal of turnover in the fund's equity portfolio, which is consistent with its investment philosophy. The London, England-based fund, which was co-founded by the three men in 2009, focuses on maintaining liquidity and seeking opportunistic methods of capital allocation that take advantage of short-term market opportunities.

    Comment?

  3. Hospira Recalls Of One Lot Of Bupivacaine HCl InjectionRead the original story w/Photo

    22 hrs ago | Pharmaceutical Processing

    Hospira, Inc. has announced today it is issuing a voluntary recall of one lot of Preservative-Free Bupivacaine HCl Injection, USP, 0.5% , 30 mL Single-dose due to one confirmed customer complaint of orange and black, visible particles embedded and free floating within a single-dose glass teartop vial. The particles were identified as iron oxide.

    Comment?

  4. Hospira Issues A Voluntary Nationwide Recall Of One Lot Of...Read the original story w/Photo

    Yesterday | US Recall News

    Hospira, Inc., has announced today it is issuing a voluntary recall of one lot of Preservative-Free Bupivacaine HCl Injection, USP, 0.5% , 30 mL Single-dose due to one confirmed customer complaint of orange and black, visible particles embedded and free floating within a single-dose glass teartop vial. The particles were identified as iron oxide.

    Comment?

  5. Hospira Leadership Presents at Preeminent European Biosimilars Forum, ...Read the original story

    Yesterday | Freshnews

    Hospira, Inc. , a world leader in the development of biosimilar therapies, spoke about the importance of extrapolation in bringing biosimilars to patients today at the European Generics Association annual European Biosimilars Group conference in London. Speaking at the EGA conference, Sumant Ramachandra, M.D., Ph.D., senior vice president and chief scientific officer, Hospira, and one of the authors of the white paper, said, "Extrapolation is fundamental to biosimilar manufacturers who are delivering high quality biologic medicines at competitive prices.

    Comment?

  6. Pfizer Hosts Annual Meeting Of ShareholdersRead the original story

    Wednesday Apr 22 | BioSpace

    The board of directors of Pfizer Inc. today declared a 28-cent second-quarter 2015 dividend on the company's common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015. The second-quarter 2015 cash dividend will be the 306th consecutive quarterly dividend paid by Pfizer.

    Comment?

  7. Bullied in Norway, Merck Sees Sales of Blockbuster PlungeRead the original story

    Wednesday Apr 22 | The Washington Post

    The first salvo was fired in February when Orion Oyj cut the local price for a copycat version of Merck & Co.' s blockbuster arthritis medicine Remicade by 69 percent of the original drug's cost.

    Comment?

  8. Pfenex Inc. Shifts Focus In-House To Develop Biosimilar To BetaseronRead the original story w/Photo

    Wednesday Apr 22 | Seeking Alpha

    A surprise announcement was made during Pfenex Inc.'s fourth-quarter conference call. When Hospira made an offer for the biosimilar to Lucentis that PFNX could not refuse, PFNX realized a need to fill the gap in its pipeline.

    Comment?

  9. Merck Gets Bullied in Norway With - Knock-Out' Remicade PriceRead the original story

    Wednesday Apr 22 | The Washington Post

    The first salvo was fired in February when Orion Oyj cut the local price for a copycat version of Merck & Co.' s blockbuster arthritis medicine Remicade by 69 percent of the original drug's cost.

    Comment?

  10. Merck Gets Bullied in Norway With - Knock-Out' Remicade Price CutRead the original story

    Wednesday Apr 22 | The Washington Post

    The first salvo was fired in February when Orion Oyj cut the local price for a copycat version of Merck & Co.' s blockbuster arthritis medicine Remicade by 69 percent of the original drug's cost.

    Comment?

  11. Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On MylanRead the original story w/Photo

    Tuesday Apr 21 | Seeking Alpha

    The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, today with an approach worth around $40bn, it looks like the action is unlikely to grind to a halt anytime soon. To put the first quarter in context, more money was pledged in this period than was spent in either 2012 or 2011.

    Comment?

  12. James Pallotta's Raptor Capital Hits Homerun with Hospira, Inc.Read the original story w/Photo

    Friday Apr 17 | Insider Monkey

    Raptor Capital Management is a hedge fund founded by James Pallotta . As a part of Raptor Group Holdings, this hedge fund specializes in investing in public and private equities across a broad variety of sectors, regions and asset classes.

    Comment?

  13. John Rogers' Ariel Fund Q1 2015 CommentaryRead the original story

    Thursday Apr 16 | GuruFocus.com

    Investing in small- and mid-cap stocks is riskier and more volatile than investing in large-cap stocks. The intrinsic value of the stocks in which the Fund invests may never be recognized by the broader market.

    Comment?

  14. 4 Big Biopharma Deals We Might See In 2015Read the original story w/Photo

    Thursday Apr 16 | Seeking Alpha

    Based on these trends, here are 4 big deals we may see this year involving big name firms like Pfizer, Gilead, Merck, Shire, and Celgene. In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline .

    Comment?

  15. Hope for Greater Access for Patients to Biosimilar MedicinesRead the original story

    Monday Apr 13 | Freshnews

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, said at the World Health Organization in Geneva, Switzerland, today that it is essential for biosimilar drugs to be given the same nonproprietary names as original biologics to ensure that patients receive the full benefit of greater access and lower costs that these medicines can bring.

    Comment?

  16. Mizuho Analyst On The Fence At Medicines Co. Pending Patent AppealRead the original story

    Saturday Apr 11 | Benzinga

    Uncertainty over patents on The Medicines Company 's lead blood-clot drug Angiomax will hurt results going forward, an analyst said Friday. Hospira, Inc. is set to launch a generic version of Angiomax in June under a court ruling concerning a patent dispute last year.

    Comment?

  17. Where to Look for Opportunities When Markets Are Looking for DirectionRead the original story w/Photo

    Thursday Apr 9 | TheStreet.com

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

    Comment?

  18. Bet On M&A Frenzy With These ETFs And StocksRead the original story w/Photo

    Thursday Apr 9 | Seeking Alpha

    This is primarily thanks to low interest rates, cheap borrowing cost, healthy cash reserves, hunt for higher growth and a strong dollar. According to the latest data released by Dealogic , the value of M&A across the globe rose 23% year over year in the first quarter of this year to $902.2 billion.

    Comment?

  19. Profit uncaged: 12 unstoppable companiesRead the original story w/Photo

    Wednesday Apr 8 | USA Today

    There are 12 companies in the Standard & Poor's 500, including aluminum maker Alcoa , oil driller Transocean and accessories designer Michael Kors that have torn past adjusted earnings forecasts for each and every of the past four straight quarters by 10% or more, according to a USA TODAY review of data from S&P Capital IQ. Companies that rip the doors off expectations are huge winners for investors, too.

    Comment?

  20. Hospira Slapped Again By the FDA for Plant ProblemsRead the original story

    Tuesday Apr 7 | BioSpace

    Hospira Inc, which agreed in February to be bought by Pfizer Inc, said the U.S. Food and Drug Administration had sent it another warning letter detailing violations in standard drug manufacturing practices at one of its facilities. The FDA said its inspectors had visited the company's plant in Liscate, Italy twice in May last year and identified significant violations, including a failure to establish procedures to prevent contamination and to thoroughly investigate instances where a batch did not meet specifications.

    Comment?